The creation of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, involves a complex complicated synthetic process. Preliminary routes focused on amino acid chain section coupling, utilizing solid-phase creation methodologies to build the long protein sequence. Subsequent